KRAS: Finally a druggable target in oncology?
- 01.12.2024
- editorial
Erschienen in:
- Verfasst von
- Aysegul Ilhan-Mutlu, MD, PhD
- Erschienen in
- memo - Magazine of European Medical Oncology | Ausgabe 4/2024
Auszug
After the initial establishment of microsatellite instability (MSI) as a tissue-agnostic biomarker, medical oncology is increasingly faced with other biomarkers that are assessed beyond tumor tissue type and have appropriate treatment options [1]. Although Kirsten rat sarcoma viral oncogene homologue (KRAS) was discovered as one of the first oncogenes, direct inhibition of the KRAS molecule has not yet been possible. Evaluating KRAS status helped us to implement upstream or downstream inhibitor molecules as this was considered a predictive biomarker [2]. …
Anzeige
- Titel
- KRAS: Finally a druggable target in oncology?
- Verfasst von
-
Aysegul Ilhan-Mutlu, MD, PhD
- Publikationsdatum
- 01.12.2024
- Verlag
- Springer Vienna
- Erschienen in
-
memo - Magazine of European Medical Oncology / Ausgabe 4/2024
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076 - DOI
- https://doi.org/10.1007/s12254-024-01004-5
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.